High-Sensitivity Cardiac Troponin I Enhances Preeclampsia Prediction Beyond Maternal Factors and the sFlt-1/PlGF Ratio
Circulation · 2024
DOI: 10.1161/circulationaha.123.066199 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, 2024. Verfasst von Lucas Bacmeister und 17 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Medical Center-University of Freiburg, Faculty of Medicine, Univ…. Hauptthemen laut MEDLINE: Pre-Eclampsia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Preeclampsia shares numerous risk factors with cardiovascular diseases. Here, we aimed to assess the potential utility of high-sensitivity cardiac troponin I (hs-cTnI) values during pregnancy in predicting preeclampsia occurrence. METHODS: This study measured hs-cTnI levels in 3721 blood samples of 2245 pregnant women from 4 international, prospective cohorts. Three analytical approaches were used: (1) a cross-sectional analysis of all women using a single blood sample, (2) a longitudinal analysis of hs-cTnI trajectories in women with multiple samples, and (3) analyses of prediction models incorporating hs-cTnI, maternal factors, and the sFlt-1 (soluble fms-like tyrosine kinase 1)/PlGF (placental growth factor) ratio. RESULTS: Women with hs-cTnI levels in the upper quarter had higher odds ratios for preeclampsia occurrence compared with women with levels in the lower quarter. Associations were driven by preterm preeclampsia (odds ratio, 5.78 [95% CI, 2.73–12.26]) and remained significant when using hs-cTnI as a continuous variable adjusted for confounders. Between-trimester hs-cTnI trajectories were independent of subsequent preeclampsia occurrence. A prediction model incorporating a practical hs-cTnI level of detection cutoff (≥1.9 pg/mL) alongside maternal factors provided comparable performance with the sFlt-1/PlGF ratio. A comprehensive model including sFlt-1/PlGF, maternal factors, and hs-cTnI provided added value (cross-validated area under the receiver operator characteristic, 0.78 [95% CI, 0.73–0.82]) above the sFlt-1/PlGF ratio alone (cross-validated area under the receiver operator characteristic, 0.70 [95% CI, 0.65–0.76]; P =0.027). As assessed by likelihood ratio tests, the addition of hs-cTnI to each prediction model significantly improved the respective prediction model not incorporating hs-cTnI, particularly for preterm preeclampsia. Net reclassification improvement analyses indicated that incorporating hs-cTnI improved risk prediction predominantly by correctly reclassifying women with subsequent preeclampsia occurrence. CONCLUSIONS: These exploratory findings uncover a potential role for hs-cTnI as a complementary biomarker in the prediction of preeclampsia. After validation in prospective studies, hs-cTnI, alongside maternal factors, may either be considered as a substitute for angiogenic biomarkers in health care systems where they are sparce or unavailable, or as an enhancement to established prediction models using angiogenic markers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinic for Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Germany (L.B., A. Buellesbach, D.W.).
- Department of Cardiology (A.G., S.B., T.Z.), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA (A. Birukov).
- Department of Molecular Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbrücke, Nuthetal (A. Birukov).
- Maternal & Fetal Health Research Centre, Faculty Biology, Medicine & Health, University of Manchester, United Kingdom (J.E.M., S.T.T., S.L.).
- Department of Endocrinology, Odense University Hospital (M.S.A.), University of Southern Denmark, Odense.
ORCID-Profile: Lucas Bacmeister, Alina Goßling, Annette Buellesbach, Anna Birukov, Jenny E Myers, Jan S Jorgensen, Anke Diemert, Kurt Hecher, Florian Herse, Stefan Blankenberg, Ralf Dechend, Dirk Westermann, Tanja Zeller
Zitieren
APA
Bacmeister, L., Goßling, A., Buellesbach, A., Birukov, A., Myers, J. E., Thomas, S. T., Lee, S., Andersen, M. S., Jorgensen, J. S., Diemert, A., Blois, S. M., Arck, P. C., Hecher, K., Herse, F., Blankenberg, S., Dechend, R., Westermann, D., & Zeller, T. (2024). High-Sensitivity Cardiac Troponin I Enhances Preeclampsia Prediction Beyond Maternal Factors and the sFlt-1/PlGF Ratio. Circulation. https://doi.org/10.1161/circulationaha.123.066199
Vancouver
Bacmeister L, Goßling A, Buellesbach A, Birukov A, Myers JE, Thomas ST, et al. High-Sensitivity Cardiac Troponin I Enhances Preeclampsia Prediction Beyond Maternal Factors and the sFlt-1/PlGF Ratio. Circulation. 2024. doi:10.1161/circulationaha.123.066199
BibTeX
@article{Bacmeister2024,
author = {Bacmeister, Lucas and Goßling, Alina and Buellesbach, Annette and Birukov, Anna and Myers, Jenny E and Thomas, Susan T and Lee, Stacy and Andersen, Marianne S and Jorgensen, Jan S and Diemert, Anke and Blois, Sandra M and Arck, Petra C and Hecher, Kurt and Herse, Florian and Blankenberg, Stefan and Dechend, Ralf and Westermann, Dirk and Zeller, Tanja},
title = {High-Sensitivity Cardiac Troponin I Enhances Preeclampsia Prediction Beyond Maternal Factors and the sFlt-1/PlGF Ratio},
journal = {Circulation},
year = {2024},
doi = {10.1161/circulationaha.123.066199}
}
EUVIMED